Boyd, M., Ross, S., Owens, J., Hunter, D., Babich, J., Zalutsky, M., Hamilton, T., Bell, S. and Mairs, R. (2004) Preclinical evaluation of no-carrier-added [131I]meta-iodobenzyl guanidine, for the treatment of tumours transfected with the noradrenaline transporter gene. Letters in Drug Design and Discovery, 1, pp. 50-57.
Full text not currently available from Enlighten.
Abstract
Meta-[131I]iodobenzylguanidine ([131I]MIBG), used for neuroblastoma treatment, binds to the noradrenaline transporter (NAT). After NAT gene transfection, other tumour types might be treatable with [131I]MIBG. At 14 MBq, carrier-added [131I]MIBG (1110 MBq/mg) delayed tumour regrowth in NAT gene-transfected xenografts by 39-days, while no-carrier-added [131I]MIBG (>104 GBq/mg) cured 100% of tumours
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Mairs, Professor Robert and Boyd, Dr Marie |
Authors: | Boyd, M., Ross, S., Owens, J., Hunter, D., Babich, J., Zalutsky, M., Hamilton, T., Bell, S., and Mairs, R. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
Journal Name: | Letters in Drug Design and Discovery |
ISSN: | 1570-1808 |
University Staff: Request a correction | Enlighten Editors: Update this record